<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04056390</url>
  </required_header>
  <id_info>
    <org_study_id>SF124/2017</org_study_id>
    <nct_id>NCT04056390</nct_id>
  </id_info>
  <brief_title>Ablation STrategies for Repeat PrOcedures in Patients With Atrial Fibrillation Recurrences</brief_title>
  <acronym>ASTRO AF</acronym>
  <official_title>Ablation STrategies for Repeat PrOcedures in Patients With Atrial Fibrillation Recurrences</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardioangiologisches Centrum Bethanien</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>CRO Kottmann</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cardioangiologisches Centrum Bethanien</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate different ablation strategies in patients with AF
      recurrences despite chronic PVI after prior catheter ablation.

      The present study is a multi-centre prospective randomized study enrolling 256 patients with
      drug-refractory AF despite previous AF ablation.

      After PV remapping confirming durable PVI patients will be assigned to 2 different groups:
      Group A: Substrate modification.

      After obtaining a voltage map of the LA, substrate modification will be performed aiming at
      low-voltage areas (LVA) &lt; 0.5mV.

      Group B: LAA isolation. Patients will undergo LAA-isolation using the cryoballoon (CB).
      Catheter ablation procedures will be performed with commercially available devices including
      3D mapping systems (CARTO, EnSite) and irrigated radiofrequency current (RFC) ablation or
      cryothermal balloon ablation (Arctic Front Advance).

      The primary endpoint is freedom from documented recurrence of AF or any atrial
      tachyarrhythmia lasting &gt; 30 seconds between day 91 and 365 after the index procedure.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2019</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Arrhythmia Recurrence</measure>
    <time_frame>Day 91-365 after index ablation</time_frame>
    <description>Freedom from AF/AT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of periprocedural complications</measure>
    <time_frame>day 0 - day 365</time_frame>
    <description>Incidence of periprocedural complications such as cardiac perforation, thromboembolic events or bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of electrical cardioversions and hospitalizations</measure>
    <time_frame>day0 - day 365</time_frame>
    <description>Number of electrical cardioversions and hospitalizations</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">256</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Substrate Modification</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After obtaining a voltage map of the LA, substrate modification by catheter ablation using an irrigated radio frequency current ablation catheter will be performed aiming at low-voltage areas (LVA) &lt; 0.5mV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LAA Isolation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will undergo LAA-isolation using the cryoballoon (CB). Six weeks later patients will undergo re-mapping. In case of residual conduction LAA-reisolation will be performed. In case of durable LAA isolation, interventional LAA occlusion is recommended.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Catheter ablation using irrigated radiofrequency current ablation or cryothermal energy</intervention_name>
    <description>Substrate ablation in terms of voltage abatement versus electrical left atrial appendage isolation.</description>
    <arm_group_label>LAA Isolation</arm_group_label>
    <arm_group_label>Substrate Modification</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  • Symptomatic non-valvular atrial fibrillation despite prior ablation with an
             indication for re-ablation according to current guidelines.

               -  Permanent pulmonary vein isolation according to mapping with a spiral mapping
                  catheter

               -  Age 18-85 years.

               -  Left atrial size &lt; 55mm.

               -  Left ventricular ejection fraction ≥ 45%.

               -  Patient is able to provide informed consent and is willing to comply with the
                  study protocol.

        Exclusion Criteria:

          -  Contraindications for repeat ablation

          -  Reconnected pulmonary veins according to mapping results with a spiral mapping
             catheter

          -  Minimal diameter of LAA neck ≥25mm

          -  History of mitral valve surgery

          -  Severe mitral valve regurgitation

          -  Inability to be treated with oral anticoagulation

          -  Presence of intracardiac thrombi

          -  Chronic obstructive pulmonary disease treated with long acting bronchodilatators

          -  Asthma

          -  Obstructive sleep apnea syndrome

          -  Pregnancy

          -  Participation in other clinical studies

          -  Unwilling to follow the study protocol and to attend follow-up visits
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boris Schmidt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardioangiologisches Centrum Bethanien</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Boris Schmidt, MD</last_name>
    <phone>004969945028</phone>
    <phone_ext>0</phone_ext>
    <email>b.schmidt@ccb.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maria Sikorski</last_name>
    <phone>0049945028</phone>
    <phone_ext>0</phone_ext>
    <email>m.sikorski@ccb.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cardioangiologisches Centrum Bethanien</name>
      <address>
        <city>Frankfurt/Main</city>
        <zip>60431</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Boris Schmidt, Dr.</last_name>
      <phone>+4969945028</phone>
      <phone_ext>110</phone_ext>
      <email>b.schmidt@ccb.de</email>
    </contact>
    <investigator>
      <last_name>Boris Schmidt, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig Holstein</name>
      <address>
        <city>Lübeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rolan R Tilz, MD</last_name>
      <phone>+49 451 500</phone>
      <phone_ext>44580</phone_ext>
      <email>Roland.Tilz@uksh.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 12, 2019</study_first_submitted>
  <study_first_submitted_qc>August 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2019</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>catheter ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

